Farxiga Restarting After Acute Illness: A Clinician's Protocol

Why Dapagliflozin Must Be Held During Acute Illness

Dapagliflozin blocks sodium-glucose cotransporter-2 (SGLT2) in the proximal tubule, causing roughly 60 to 90 grams of urinary glucose loss daily regardless of plasma glucose concentration. During physiologic stress, this glucosuria continues while counterregulatory hormones drive ketogenesis. The result is euglycemic diabetic ketoacidosis (euDKA), a form of DKA that is missed on standard glucose monitoring.

The FDA issued a Drug Safety Communication in 2015 and updated it in 2020 warning that SGLT2 inhibitors, including dapagliflozin, cause euDKA, defined as arterial pH <7.3 with ketones elevated but glucose often below 250 mg/dL. Cases have occurred in patients with type 1 diabetes, type 2 diabetes, and even in off-label use. 1

The Physiologic Mechanism During Illness

Acute illness raises glucagon, cortisol, epinephrine, and growth hormone. These hormones suppress insulin secretion and accelerate hepatic ketogenesis. In a patient taking dapagliflozin, urinary glucose loss continues, so the liver never receives the suppressive glucose signal that would ordinarily blunt ketone production. The dual hit of elevated counterregulatory hormones and persistent SGLT2-driven glucosuria creates a ketosis-permissive environment even when blood glucose remains near normal. 2

Which Illnesses Trigger the Hold

Any condition that reduces oral intake, causes vomiting or diarrhea, or requires hospitalization meets the threshold. The following situations require immediate dapagliflozin cessation:

• Febrile illness lasting more than 24 hours
• Gastroenteritis with more than two episodes of vomiting or diarrhea
• Surgical procedures (elective or emergent), FDA labeling recommends holding at least 3 days before elective surgery 3
• Acute heart failure decompensation requiring IV diuretics
• Sepsis or any hemodynamic instability
• Administration of iodinated contrast media (hold the day of contrast and for 48 hours after if eGFR is borderline)
• Reduced oral intake for any reason lasting more than 12 hours

Patients and caregivers should receive written "sick day rules" at every clinic visit. A 2022 analysis in Diabetes Care found that fewer than 35% of patients on SGLT2 inhibitors had received written sick-day guidance from their prescriber, despite clear guideline recommendations. 4

The Clinical Evidence Behind Dapagliflozin's Approved Indications

Understanding why dapagliflozin is worth restarting carefully, rather than simply discontinuing permanently, requires knowing the magnitude of benefit it provides across three distinct populations.

Heart Failure: DAPA-HF

The DAPA-HF trial (N=4,744) randomized patients with heart failure with reduced ejection fraction (HFrEF, LVEF <40%) to dapagliflozin 10 mg daily or placebo on top of standard guideline-directed medical therapy. Over a median follow-up of 18.2 months, dapagliflozin produced a 26% relative risk reduction in the composite of worsening heart failure or cardiovascular death (HR 0.74, 95% CI 0.65 to 0.85, P<0.001). 5

The benefit appeared within 28 days and was consistent regardless of diabetes status. About 45% of DAPA-HF participants did not have diabetes. That finding changed prescribing across cardiology. 5

Chronic Kidney Disease: DAPA-CKD

DAPA-CKD (N=4,304) enrolled adults with CKD stages 2 to 4 (eGFR 25 to 75 mL/min/1.73 m²) and urine albumin-to-creatinine ratio of 200 to 5000 mg/g. Dapagliflozin reduced the composite of sustained eGFR decline ≥50%, end-stage kidney disease, or renal or CV death by 39% (HR 0.61, 95% CI 0.51 to 0.72, P<0.001). 6

The trial was stopped early because the benefit was so clear. About 33% of participants had type 1 diabetes or no diabetes at all. 6

Type 2 Diabetes: DECLARE-TIMI 58

DECLARE-TIMI 58 (N=17,160) examined dapagliflozin in a broad T2D population with or without established cardiovascular disease. The drug reduced the rate of hospitalization for heart failure or CV death by 17% (HR 0.83, 95% CI 0.73 to 0.95) compared with placebo, with no significant difference in major adverse cardiovascular events in the full cohort. 7

These three datasets together explain why clinicians go to considerable effort to restart dapagliflozin safely after illness rather than simply leaving it discontinued.

Restart Criteria: A Step-by-Step Framework

Safe restart requires satisfying five domains. Checking off each one reduces the risk of restart-associated euDKA to a level comparable to baseline therapy risk.

Domain 1: Nutritional Status

The patient must be eating and drinking normally for a minimum of 48 hours. "Normally" means consuming at least 50% of their usual daily caloric intake by mouth without vomiting or diarrhea. If they are still on clear liquids or tube feeds without full carbohydrate delivery, restart should wait. 8

Domain 2: Hemodynamic Stability

Blood pressure should be at or near the patient's baseline without vasopressor support. Acute illness causes volume contraction; dapagliflozin's osmotic diuresis compounds this. The 2023 ADA Standards of Care note that SGLT2 inhibitors may cause modest blood pressure reductions (systolic 3 to 5 mmHg) and should be used cautiously when volume depletion is a concern. 9

Domain 3: Renal Function

Obtain a basic metabolic panel before restarting. The current FDA label for dapagliflozin permits use down to eGFR ≥25 mL/min/1.73 m² for CKD and heart failure indications. 3 For type 2 diabetes as a glucose-lowering indication, the glycemic benefit is negligible below eGFR 45 mL/min/1.73 m² given reduced tubular glucose filtration. If eGFR has dropped more than 20% below pre-illness baseline, nephrology input should precede restart.

Domain 4: Ketone Clearance

Check serum beta-hydroxybutyrate or urine ketones before resuming dapagliflozin. If serum beta-hydroxybutyrate exceeds 1.0 mmol/L or urine ketones are moderate to large, do not restart until the value normalizes. A 2021 review in the Journal of Clinical Endocrinology and Metabolism identified elevated ketones at restart as the single most actionable pre-restart lab finding for predicting euDKA. 10

Domain 5: Precipitating Cause Resolved

If the illness was an infection, the patient should be afebrile for at least 24 hours and completing a defined antibiotic course. If the admission was for acute heart failure decompensation, the patient should be at or near dry weight with stable diuretic dosing before restarting the SGLT2 inhibitor on an outpatient basis.

Perioperative Holding and Restart: Specific Timelines

Surgery deserves its own section because the hold duration depends on procedure type, anesthesia type, and expected recovery.

Elective Surgery

The FDA label explicitly recommends holding dapagliflozin at least 3 days before elective procedures. 3 The Society for Endocrinology consensus published in 2021 extended this to 4 days for major abdominal surgery given longer NPO requirements and the metabolic stress of abdominal procedures. 11

Restart after elective surgery follows the five-domain framework above. Most outpatient procedures (colonoscopy, minor orthopedic surgery) allow restart within 24 to 48 hours if the patient is eating and has no signs of ketosis.

Emergency Surgery

For emergency operations, there is no pre-operative hold window. The anesthesia team should be informed that the patient is on a SGLT2 inhibitor so that intraoperative ketone monitoring can occur. Post-operatively, restart follows the standard five-domain framework, typically 48 to 72 hours after the patient resumes oral intake. 12

Cardiac Procedures

Cardiac catheterization with iodinated contrast requires a 48-hour hold after contrast administration when eGFR is between 30 and 60 mL/min/1.73 m². Below eGFR 30, the decision to restart dapagliflozin should include nephrology input. Above eGFR 60, the evidence for contrast-related harm is weaker, but many centers hold for 24 hours as a precaution given the osmotic stress of contrast itself. 13

Dosing After Restart: What Changes and What Does Not

Nothing changes in the dose. Dapagliflozin is approved at a single oral dose of 10 mg once daily for all three indications (T2D, HF, CKD), and no titration or dose escalation is required after a hold period. 3

There is no loading dose, no restart titration schedule, and no requirement to recheck HbA1c or NT-proBNP before resuming. The pharmacodynamic effect (urinary glucose excretion) returns within hours of the first post-hold dose, reaching steady-state plasma concentrations within 3 days. 14

Patients on concomitant insulin or sulfonylureas should have those agents reviewed at restart, because dapagliflozin's glucose-lowering action re-engages immediately and may increase hypoglycemia risk when stacked with insulin. A dose reduction of 10 to 20% in short-acting insulin is reasonable at restart if pre-illness doses were causing hypoglycemia. 9

Recognizing and Managing Euglycemic DKA at Restart

EuDKA after SGLT2 inhibitor restart is rare but life-threatening. The clinical picture differs from classic hyperglycemic DKA, which is why it is missed.

Presentation

The patient presents with nausea, vomiting, and abdominal pain, but glucose is often 140 to 200 mg/dL, levels that do not trigger a DKA workup by reflex. Blood gas shows pH <7.3 and bicarbonate <18 mEq/L. Anion gap is elevated. Beta-hydroxybutyrate exceeds 3.0 mmol/L. 15

A 2019 case series in Diabetes Care (N=42) found that the median glucose at euDKA presentation was 186 mg/dL, well below the 250 mg/dL threshold that most clinicians use to order a ketone panel. 16

Management

Stop dapagliflozin immediately. Provide IV dextrose even if glucose is near normal. The goal is to suppress ketogenesis by restoring insulin secretion through carbohydrate delivery. Administer insulin per standard DKA protocols but be aware that insulin requirements may be lower than in hyperglycemic DKA because the underlying glucose is already normal. Replace potassium aggressively. The American Diabetes Association's 2024 Standards of Care include a specific euDKA management pathway for SGLT2 inhibitor-associated cases. 9

Special Populations: Heart Failure and CKD Patients Post-Hospitalization

Patients with heart failure or CKD represent the populations where dapagliflozin's cardiorenal benefits are largest. They are also the patients most likely to experience acute illness-related holds, and the restart decision requires extra nuance.

Post-Acute Heart Failure Hospitalization

DAPA-HF demonstrated a 26% reduction in worsening HF or CV death. 5 Withholding dapagliflozin indefinitely after an HF hospitalization eliminates that protection. The 2022 AHA/ACC/HFSA guideline for heart failure (a Class I recommendation for SGLT2 inhibitors in HFrEF) explicitly supports resuming the drug at discharge once congestion has been adequately treated. 17

Discharge eGFR is frequently lower than baseline after an acute decompensation. If eGFR at discharge is ≥25 mL/min/1.73 m², dapagliflozin may be restarted for HF and CKD indications even though the glucose-lowering benefit is negligible at that eGFR. 3

Post-AKI CKD Patients

An acute kidney injury episode during hospitalization causes a temporary eGFR nadir. DAPA-CKD showed a 39% reduction in kidney disease progression. 6 The question clinicians face is whether to restart before eGFR has returned to baseline.

The practical answer is to recheck eGFR at 2 weeks post-discharge. If eGFR has returned to within 15% of the pre-illness value and is still ≥25 mL/min/1.73 m², restart is appropriate. A persistent eGFR drop of more than 25% from pre-illness baseline warrants nephrology review before resuming.

Patient Education: The Sick Day Rules Card

Every patient prescribed dapagliflozin should carry a written sick day reference. The core instructions:

1. Stop Farxiga if you cannot eat or drink normally.
2. Stop Farxiga the day before any scheduled surgery or procedure.
3. Check your ketones (urine or blood) if you feel nauseated, vomit, or feel unusually tired.
4. Go to the emergency department if ketones are moderate or large, even if your blood sugar is normal.
5. Call your prescriber before restarting Farxiga after any illness lasting more than 2 days.
6. Do not skip restarting on your own, the risks of stopping permanently can outweigh the short-term risks of the drug. 18

The Endocrine Society's 2021 clinical practice guideline on diabetes and hospitalization recommends that SGLT2 inhibitor sick day rules be provided in writing and reviewed verbally at every visit. 19

"Patients with heart failure or CKD on SGLT2 inhibitors derive substantial long-term benefit and should not have these agents discontinued at discharge without a clear plan and date for resumption," stated the 2022 AHA/ACC/HFSA Heart Failure Guideline Writing Committee. 17

Monitoring After Restart: What to Check and When

Restart is not the final step. A brief monitoring window reduces risk.

Week 1 Post-Restart Labs

Obtain a basic metabolic panel 5 to 7 days after restarting dapagliflozin when the patient had an illness severe enough to require hospitalization. The key values are:

• Serum creatinine and eGFR (confirm return to baseline)
• Serum potassium (SGLT2 inhibitors may cause mild potassium shifts in CKD patients on renin-angiotensin-aldosterone system blockers) 20
• Blood pressure (confirm no excess hypotension from combined osmotic and diuretic effects)

Symptom Monitoring

Patients should report any new nausea, vomiting, or abdominal discomfort within the first week of restart. These symptoms in the absence of obvious gastroenteritis should trigger a ketone check. A serum beta-hydroxybutyrate above 1.5 mmol/L warrants withholding the drug and contacting the prescriber.

Genital mycotic infections may transiently increase after restart as urinary glucose excretion resumes. A 2019 meta-analysis of 34 SGLT2 inhibitor trials (N=64,296) found a relative risk of 3.37 (95% CI 2.89 to 3.93) for genital infections vs. Placebo. 21 Patients with a history of recurrent mycotic infections should be counseled at restart.